

Putting NICE guidance into practice

**Resource impact statement:  
Belimumab for treating active  
autoantibody-positive systemic lupus  
erythematosus (TA397)**

Published: June 2016

Belimumab is recommended as an option as add-on treatment for active autoantibody-positive systemic lupus erythematosus in adults only if criteria in the recommendations of the [guidance](#) are met.

It is unlikely that the guidance will result in a significant change in resource use in the NHS because the population eligible for treatment is low. There is a patient access scheme which comprises a simple discount. The level of the discount is commercial in confidence.

The commissioner for this topic is NHS England. Providers are secondary care providers (hospitals) and specialist centres. This topic falls within programme budgeting category 15 'Problems of the musculo skeletal system'.

## About this resource impact statement

This resource impact statement accompanies the NICE technology appraisal guidance on [Belimumab for treating active autoantibody-positive systemic lupus erythematosus TA397](#) and should be read in conjunction with it. See [terms and conditions](#) on the NICE website.

### **This statement is written in the following context**

This statement represents the view of NICE, which was arrived at after careful consideration of the available data and through consulting healthcare professionals. The statement is an implementation tool and focuses on the recommendations that were considered to have a significant impact on national resource use.

Assumptions used in the statement are based on assessment of the national average. Local practice may be different from this, and the impact should be estimated locally.

Implementation of the guidance is the responsibility of local commissioners and providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this costing tool should be interpreted in a way that would be inconsistent with compliance with those duties.

© National Institute for Health and Care Excellence, 2016. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.